Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCPH POWR Grades
- Value is the dimension where DCPH ranks best; there it ranks ahead of 67.86% of US stocks.
- The strongest trend for DCPH is in Momentum, which has been heading down over the past 48 weeks.
- DCPH ranks lowest in Momentum; there it ranks in the 9th percentile.
DCPH Stock Summary
- DCPH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 375.68 -- higher than 92.02% of US-listed equities with positive expected earnings growth.
- With a price/sales ratio of 23.14, Deciphera Pharmaceuticals Inc has a higher such ratio than 91.34% of stocks in our set.
- Revenue growth over the past 12 months for Deciphera Pharmaceuticals Inc comes in at 1,069.8%, a number that bests 98.94% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Deciphera Pharmaceuticals Inc are BPMC, RYTM, FIXX, ZGNX, and OVID.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Valuation Summary
- DCPH's price/sales ratio is 21.9; this is 476.32% higher than that of the median Healthcare stock.
- DCPH's price/sales ratio has moved NA NA over the prior 48 months.
- DCPH's price/sales ratio has moved NA NA over the prior 48 months.
Below are key valuation metrics over time for DCPH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCPH | 2021-08-31 | 21.9 | 4.1 | -7.1 | -6.8 |
| DCPH | 2021-08-30 | 21.7 | 4.1 | -7.0 | -6.8 |
| DCPH | 2021-08-27 | 21.2 | 4.0 | -6.9 | -6.6 |
| DCPH | 2021-08-26 | 20.5 | 3.8 | -6.6 | -6.4 |
| DCPH | 2021-08-25 | 20.6 | 3.9 | -6.7 | -6.4 |
| DCPH | 2021-08-24 | 19.7 | 3.7 | -6.4 | -6.1 |
DCPH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCPH has a Quality Grade of D, ranking ahead of 20.91% of graded US stocks.
- DCPH's asset turnover comes in at 0.137 -- ranking 231st of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DCPH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.137 | 0.980 | -0.586 |
| 2021-03-31 | 0.104 | 0.993 | -0.553 |
| 2020-12-31 | 0.062 | 0.995 | -0.544 |
| 2020-09-30 | 0.033 | 0.996 | -0.556 |
| 2020-06-30 | 0.011 | 0.999 | -0.565 |
| 2020-03-31 | 0.044 | 1.000 | -0.565 |
DCPH Price Target
For more insight on analysts targets of DCPH, see our DCPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $68.50 | Average Broker Recommendation | 1.4 (Strong Buy) |
DCPH Stock Price Chart Interactive Chart >
DCPH Price/Volume Stats
| Current price | $33.93 | 52-week high | $68.40 |
| Prev. close | $32.79 | 52-week low | $26.20 |
| Day low | $32.81 | Volume | 413,200 |
| Day high | $34.27 | Avg. volume | 411,428 |
| 50-day MA | $31.13 | Dividend yield | N/A |
| 200-day MA | $40.38 | Market Cap | 1.97B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest DCPH News From Around the Web
Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Deciphera Presents New Data Across Pipeline At ESMO CongressDeciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced four e-poster presentations at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021. The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib plus paclitaxel in Platinum-Resistant Ovarian Cancer (PROC) and vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT). Rebastinib plus Paclitaxel Combo demonstrated Progression-Free Survival of 9.1 months in heavily pretreat |
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal TumorWALTHAM, Mass., September 17, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of QINLOCK (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have rece |
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021WALTHAM, Mass., September 17, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced four e-poster presentations at the ESMO Congress 2021. The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib in combination with paclitaxel in patients with PROC and updated preliminary results from the ongoing Phase 1/2 study of v |
Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021WALTHAM, Mass., September 10, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET. |
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the Events and Presentations page in the Investors section of the Companys website at https://inve |
DCPH Price Returns
| 1-mo | 11.21% |
| 3-mo | -7.32% |
| 6-mo | -26.29% |
| 1-year | -32.02% |
| 3-year | -12.37% |
| 5-year | N/A |
| YTD | -40.55% |
| 2020 | -8.31% |
| 2019 | 196.52% |
| 2018 | -7.41% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching DCPH
Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...